Passumpsic Savings Bank Makes New $2.20 Million Investment in Cencora, Inc. $COR

Passumpsic Savings Bank acquired a new position in Cencora, Inc. (NYSE:COR) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 6,527 shares of the company’s stock, valued at approximately $2,204,000.

Several other large investors also recently made changes to their positions in COR. Oakworth Capital Inc. acquired a new stake in shares of Cencora in the fourth quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the fourth quarter worth $27,000. Archer Investment Corp increased its position in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the third quarter worth $30,000. Finally, Cloud Capital Management LLC acquired a new stake in Cencora during the 3rd quarter valued at $31,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of COR opened at $256.96 on Monday. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54. The company has a 50-day moving average of $314.65 and a two-hundred day moving average of $339.24. The stock has a market cap of $49.99 billion, a price-to-earnings ratio of 19.71, a PEG ratio of 1.19 and a beta of 0.64. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.59.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The firm had revenue of $78.36 billion during the quarter, compared to analyst estimates of $81.09 billion. During the same quarter in the previous year, the business earned $4.42 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, equities research analysts expect that Cencora, Inc. will post 17.76 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be issued a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on COR shares. Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. Leerink Partners reaffirmed an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Wells Fargo & Company lowered their price target on shares of Cencora from $429.00 to $331.00 and set an “overweight” rating for the company in a report on Monday, May 11th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Cencora in a report on Monday, May 4th. Finally, Robert W. Baird reduced their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Twelve equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average target price of $380.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.